Q-omics provides the consensus-scored TXLNG profile across patient tissues and cancer cell-line models. TXLNG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TXLNG is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TXLNG RNA expression shows 20,978 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where TXLNG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXLNG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXLNG survival associations across molecular data types. TXLNG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXLNG RNA expression–survival associations across cancer types. High TXLNG expression shows unfavorable associations in KIRP, CESC, LIHC and UCEC, but favorable associations in KIRC and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TXLNG RNA expression.
This table summarizes TXLNG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TXLNG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXLNG shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, STAD, HNSC and BLCA. The COAD box plot shows higher TXLNG RNA expression in tumor versus normal tissue (log2 FC = +1.139, t-test p < 0.001).
This table shows molecular features associated with TXLNG in patient tissues and cancer cell lines. In patient samples, TXLNG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TXLNG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
